No Data
Express News | [Change Report] Morgan Stanley & Co. International PLC reported that it has increased its shareholding in Helios (4593.JP) to 8.04%.
Healios KK Announces Key Management Changes
Stocks that moved the previous day part 2 PKSHA, Fujikura, Asahi Kasei ETC.
Stock Name <Code> 10-day Closing Price ⇒ Change from Previous Day Beauty Garage <3180> 1297 -110 The first half has seen a significant decrease in operating profit due to lower than planned results. Senshu Electric <9824> 5380 -240 It had experienced a sharp rise after the Earnings Reports. Fujikura <5803> 5851 -337 Profit-taking Sell and other supply-demand factors might have led to this. PKSHA Technology <3993> 3965 -280Tokai Tokyo Securities has downgraded its investment recommendation. Cosmos Pharmaceutical <3349>
Active and newly listed stocks during the morning session.
*Learning situation <2301> 2006 +231 results exceeded expectations in the previous period, with a forecast of double-digit operating profit growth for this period. *Topcon <7732> 1928 +171.5 reported to have entered the bidding process for privatization. *Nippon Paint Holdings <4612> 1093 +63 SMBC Nikko Securities has raised its target stock price. *Nippon Sheet Glass <5202> 349 +20 it is reported that they aim to release automotive glass materials from leftover materials by 2026. *Saizeriya <7581> 5820 +280 middle.
Helios Research Memo (6): Revenue for the interim period ending December 2024 will significantly increase due to the recognition of contract advance payments.
■ The performance trends of Helios <4593> 1. Performance for the interim period ending December 2024 The consolidated performance for the interim period ending December 2024 is 508 million yen in sales revenue (compared to 401 million yen in the same period last year, an increase of 372.4%), an operating loss of 1,331 million yen (compared to a loss of 1,555 million yen in the same period last year), a pre-tax loss of 2,968 million yen (compared to a loss of 1,321 million yen in the same period last year), and an interim loss attributable to the owners of the parent company of 2,958 million yen (compared to a loss of 1,392 million yen in the same period last year). The increase in sales revenue is due to a
Helios Research Memo (5): Business partnership with Alfresa and concluded a non-exclusive license agreement with an Astellas subsidiary.
■ The status of business partnerships and licensing agreements for Helios <4593> 1. Business partnership agreement with Alfresa In June 2024, a basic business partnership agreement concerning the distribution and sale of products handled by Alfresa, the leading domestic drug distribution company, was concluded, along with a purchase agreement for ordinary corporate bonds totaling 1.6 billion yen (1st and 2nd issues). The specific content of the business partnership is as follows: 1) Exclusive wholesale distribution rights for the company's pipeline products, including HLCM051, in the domestic market.
No Data